Down-regulation of A3AR signaling by IL-6-induced GRK2 activation contributes to Th17 cell differentiation

Shanshan Hu,Paipai Guo,Zhen Wang,Zhengwei Zhou,Rui Wang,Mei Zhang,Juan Tao,Yu Tai,Weijie Zhou,Wei Wei,Qingtong Wang
DOI: https://doi.org/10.1016/j.yexcr.2021.112482
IF: 4.145
2021-02-01
Experimental Cell Research
Abstract:<h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">A B S T R A C T</h2><p>IL-6-triggered Th17 cell expansion is responsible for the pathogenesis of many immune diseases including rheumatoid arthritis (RA). Traditionally, IL-6 induces Th17 cell differentiation through JAK-STAT3 signaling. In the present work, PKA inhibition reduces <em>in vitro</em> induction of Th17 cells, while IL-6 stimulation of T cells facilitates the internalization of A<sub>3</sub>AR and increased cAMP production in a GRK2 dependent manner. Inhibition of GRK2 by paroxetine (PAR) or genetic depletion of GRK2 restored A<sub>3</sub>AR distribution and prevented Th17 cell differentiation. Furthermore, <em>in vivo</em> PAR treatment effectively reduced the splenic Th17 cell proportion in a rat model of collagen-induced arthritis (CIA) which was accompanied by a significant improvement in clinical manifestations. These results indicate that IL-6-induced Th17 cell differentiation not only occurs through JAK-STAT3-RORγt but is also mediated through GRK2-A<sub>3</sub>AR-cAMP-PKA-CREB/ICER-RORγt. This elucidates the significance of GRK2-controlled cAMP signaling in the differentiation of Th17 cells and its potential application in treating Th17-driven immune diseases such as RA.</p>
oncology,cell biology
What problem does this paper attempt to address?